EGR1, EGFR and IGF1R protein expressions in non-small cell lung cancer and their clinical significances
DOI:
https://doi.org/10.3329/bjp.v11iS1.26413Keywords:
EGFR, EGR1, IGF1R, Non-small cell lung cancer, Protein expressionAbstract
The purpose of this study was to investigate the incidence and clinical significance of alterations in EGFR, IGF1R and the cell signaling pathway activities induced by them, as well as EGR1 expression in resected non-small cell lung cancer (NSCLC). The protein expressions of biomarker were evaluated by Western blotting in tissues from 19 surgically resected NSCLCs. High expressions of EGR1, EGFR and IGF1R were detected in more than 30% tumor tissues. High expressions of pErk and pAkt were detected in more than 50% paracancer tissues. There were significant correlations between the NSCLC target factors detected (p<0.05). Alterations of protein expressions of target factor detected in NSCLC were significantly associated with alterations in pathological subtype, differentiation, pathological stage, and smoking history. Positive EGR1 might be associated with good survival, while positive pErk might be associated with poor prognosis.
Downloads
197
100 Read
91
References
Chen B, Xiao F, Li B. The role of epithelial-mesenchymal transition and IGF-1R expression in prediction of gefitinib activity as the second-line treatment for advanced non-small-cell lung cancer. Cancer Invest. 2013; 31: 454-60.
Cortés-Sempere M, de Miguel MP, Pernía O. IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin though the activation of the IGFIR/Akt pathway in non-small cell lung cancer. Oncogene 2013; 32: 1274-83.
Dergunoa LV, Raevskaia NM, Volosheniuk EL, Limborskaia SA. Expression peculiarities of EGR1, neurotrophins and their receptor genes in human lung cancer and in normal lung tissue. Mol Gen Mikrobiol Virusol. 2007; 2: 25-30.
Ferraro B, Bepler G, Sharma S, et al. EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer. J Clin Oncol. 2005; 23: 1921-26.
Hirami Y, Aoe M, Tsukuda K, et al. Relation of epidermal growth factor receptor, phosphorylated-Akt, and hypoxia-inducible factor-1 alpha in non-small cell lung cancers. Cancer Lett. 2004; 214: 157-64.
Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clinic Oncol. 2003; 21: 3798-807?
Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999; 18: 81322.
Kaufmann K, Thiel G. Epidermal growth fact or and thrombin induced proliferation of immortalized human keratinocyt es is coupled to the synthesis of Egr-1, a zinc finger transcriptional regulator. J Cell Biochem. 2002; 85: 381-91.
Kim JS, Kim ES, Liu D, Nakagawa M, Uramoto H, Oka S, et al. Clinical significance of IGF1R expression in non-small-cell lung cancer. Clin Lung Cancer. 2012; 13: 136-42.
Kim JS, Kim ES, Liu D, et al. Prognostic impact of insulin receptor expression on survival of patients with non-small cell lung cancer. Cancer. 2012; 118: 2454-65.
Kim WY, Prudkin L, Feng L, et al. Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor1 receptor tyrosine kinase inhibitors. Cancer. 2012; 118: 3993-4003.
LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003; 195: 12737.
Ludovini V, Flacco A, Bianconi F, et al., Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients. Cancer Chemother Pharmacol. 2013; 71: 671-80.
McNeil LK, Starr TK, Hogquist KA. A requirement for sustain-ed ERK signaling during thymocyte positive select ion in vivo. Proc Natl Acad Sci USA. 2005; 102: 13574-79.
Morgillo F, Woo JK, Kim ES, et al. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res. 2006; 66: 10100-11.
Mukohara T, Kudoh S, Yamauchi S, et al., Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC). Lung Cancer. 2003; 41: 123-30.
Murakami A, Takahashi F, Nurwidya F. Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor. PLoS One. 2014; 9: e86459.
Nakagawa M, Uramoto H, Oka S, et al., Clinical significance of IGF1R expression in non-small-cell lung cancer. Clin Lung Cancer. 2012; 13: 136-42.
Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999; 13: 9-22.
Ning XH, Wang YZ, Bai CM, et al. Clinical significance of insulin-like growth factor-1 receptor in platinum-based chemotherapy for non-small cell lung cancer. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2010; 32: 366-70.
Ohsaki Y, Tanno S, Fujita Y et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep. 2000; 7: 603-07.
Peled N, Wynes MW, Ikeda N. Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cell Oncol (Dordr). 2013; 36: 277-88.
Revest JM, Di Blasi F, Kitchener P, et al. The MAPK pathway and Egr-1 mediate stress-related behavioral effects of glucocorticoids. Nat Neurosci. 2005; 8: 664-72.
Riedemann J, Macaulay VM. IGF1R signalling and its inhibition. Endocr Relat Cancer. 2006; 13 (Suppl 1): S33S43.
Tran TN, Selinger CI, Yu B. Alterations of insulin-like growth factor-1 receptor gene copy number and protein expression are common in non-small cell lung cancer. J Clin Pathol. 2014.
Vazquez-Martin A, Cufí S, Oliveras-Ferraros C. IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. Sci Rep. 2013; 3: 2560.
Vicent S, Lopez-Picazo JM, Toledo G, et al. ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Bri J Cancer. 2004; 90, 1047-52.
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
